NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4130
+0.0007 (+0.17%)
At close: 3:59PM EDT

0.4025 -0.01 (-2.54%)
Pre-Market: 8:00AM EDT

Stock chart is not supported by your current browser
Previous Close0.4123
Open0.4250
Bid0.4000 x 1100
Ask0.4387 x 800
Day's Range0.4000 - 0.4336
52 Week Range0.4000 - 13.0000
Volume750
Avg. Volume1,955,725
Market Cap25.599M
Beta (3Y Monthly)2.53
PE Ratio (TTM)N/A
EPS (TTM)-7.6300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • Associated Press5 days ago

    Neovasc: 4Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had profit of 51 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The medical device company posted revenue of $523,400 ...

  • CNW Group5 days ago

    Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

    Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

  • PR Newswire5 days ago

    Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara™

    VANCOUVER, March 21, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Higher Regional Court in Munich, Germany, on appeal by Neovasc, has dismissed the case in full, brought by Edwards Lifesciences CardiAQ LLC ("CardiAQ") against Neovasc in Germany. In this case, CardiAQ had originally claimed full ownership rights to one of Neovasc's European patent applications for its Tiara™ ("Tiara").

  • PR Newswire7 days ago

    Reducer Featured in Presentation at American College of Cardiology's Annual Meeting

    VANCOUVER, March 19, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that data on the Neovasc Reducer™ ("Reducer") was featured in session 725, titled, "Refractory Angina: Options for Patients With "No Options"" at the American College of Cardiology's ("ACC") 68th Annual Scientific Session and Expo ("ACC.19"). "We are pleased that today's ACC.19 session included an overview of our Reducer and its efficiency in narrowing the coronary sinus in refractory angina patients, which has resulted in an improvement in symptoms and quality of life for patients with refractory angina who were not candidates for revascularization.  A portion of the data discussed during the session was originally published in the New England Journal of Medicine in February 20151," stated Fred Colen, CEO of Neovasc.

  • PR Newswire11 days ago

    Neovasc Announces Closing of $5 Million Public Offering of Common Shares

    NASDAQ, TSX: NVCN VANCOUVER , March 15, 2019 /PRNewswire/ -   Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously ...

  • PR Newswire12 days ago

    Neovasc Completes Successful Quality System Surveillance Audit

    VANCOUVER, March 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has successfully completed its 2019 mandatory Surveillance Audit with its Notified Body, resulting in the maintenance of the Regulatory Certification (EC marking) and maintenance of the ISO 13485: 2016 certification of the quality management system.

  • CNW Group13 days ago

    Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21

    Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21

  • Benzinga13 days ago

    The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...

  • CNW Group13 days ago

    Neovasc Announces Pricing of $5 Million Public Offering of Common Shares

    VANCOUVER , March 13, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares") at a price to the public of US$0 .45 per Common Share, for aggregate gross proceeds to the Company of approximately US$5 million , before deducting the underwriting commission and estimated Offering expenses payable by the Company.  The Offering is expected to close on or about March 15, 2019 , subject to customary closing conditions. H.C. Wainwright & Co. (the "Underwriter") is acting as sole book-running manager for the Offering.

  • CNW Group14 days ago

    Neovasc Announces Proposed Public Offering of Common Shares

    Neovasc Announces Proposed Public Offering of Common Shares

  • CNW Group14 days ago

    Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares

    Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares

  • CNW Group21 days ago

    Neovasc Announces Reducer™ Implant "Live Case" at the CRT Meeting in Washington, DC

    VANCOUVER , March 5, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an implant procedure of the Neovasc Reducer™ ("Reducer") was featured in a "Live Case" broadcast at the Cardiovascular Research Technologies (CRT) meeting being held March 2-5, 2019 in Washington, DC . The implant procedure was performed by Dr. Francesco Giannini from the Maria Cecilia Hospital in Cotignola, Italy . Following the case there was a lot of interest from the CRT audience, including comments on the procedure and curiosity about the Reducer's mechanism of action.

  • CNW Group22 days ago

    Neovasc's Tiara™ Mitral Valve Replacement Technology Featured in Update Presentation at the CRT 2019 Meeting

    VANCOUVER , March 4, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in an update presentation at the Cardiovascular Research Technologies (CRT) meeting being held March 2-5, 2019 in Washington, DC . The update presentation was provided by Danny Dvir , MD, of the Cardiac Clinic & Services at the University of Washington Medical Center, and titled, "TIARA: Design, Clinical Results and Next Steps" on Sunday, March 3 rd.  The presentation provided an overview of the data from the 70 patients that have been treated to date with the Tiara mitral valve replacement device, including 25 patients in the TIARA-II European CE Mark Clinical Study, 23 patients in TIARA-I Early Feasibility Clinical Study and 22 patients in Special Access/Compassionate Use.

  • CNW Group26 days ago

    Neovasc announces closing of $5 million public offering of common shares

    VANCOUVER , Feb. 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares") at a price to the public of US$0 .45 per Common Share, for aggregate gross proceeds to the Company of approximately US$5 million , before deducting the underwriting commission and Offering expenses payable by the Company.